Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Art Vandelay AIA who wrote (2505)	4/21/1999 11:45:00 PM
From: Ed Ajootian	Read Replies (1) \| Respond to of 10280

Aw hell Art, Don't hold me to the facts buddy <g>! Just let me grouch in my corner 'till it passes. You have been paying a lot more attention to developments that I and thus I am not even worthy of responding to your learned post. But I will anyway <g>. In my simplified view of this world, I look at the last 6 months of press releases and I just see one drug study announced (Oxy). I look ahead 6 months (via Sturza) and I just see the initiation of one other study and no study results due out. Are there any study results due to be announced in the next 6 months? We've got all this scurrying around and no real, scientific progress, IMHO. In the '97 Annual Report SEPR had a target launch date of '00 for both Nori and Oxy. Neither one looks like it would get launched any earlier than '01 at this point. They thought they would have oral Levalbuterol out by '99 --- that ain't happenin' either. Interesting point about the covered call strategy -- will consider it. My point about Xopenex not being as good as claimed is in reference to the FDA letter. That letter very clearly states that SEPR made claims in its press release that are not warranted by the scientific evidence.